As significant news occurs, HSF will post updates as quickly as possible.
AbbVie has launched the AbbVie Immunology Scholarship, which is designed to provide financial support for exceptional students living with inflammatory diseases*, including psoriasis or hidradenitis suppurativa (HS), as they pursue their higher education goals.
Below is a brief overview of the scholarship for your reference.
UCSF Dermatology Post-Doctoral Fellowship in Clinical Research
The UCSF Department of Dermatology’s Program for Clinical Research is thrilled to announce the availability of a 1-2 year postdoctoral research fellowship for starting July 1st 2018.
The primary areas of interest include epidemiology, public health and investigator-initiated clinical trials. The postdoc would join a dynamic research team that works on a wide range of topics: inflammatory skin diseases, hidradenitis suppurativa, atopic dermatitis, geriatric dermatology, skin cancer, and the use of social media in medicine.
– US Citizen or US Permanent Resident
– Must have an MD or PhD by June 30th 2018
Research experience in study design and analysis and the use of statistical software programs is preferred. Applicants from groups traditionally underepresented in medicine (UIM) are encouraged to apply.
Interested candidates should submit their CV, a 1-page letter summarizing their professional goals and research experience and 3 reference letters by March 24th 2018 to Jeanette.firstname.lastname@example.org.
ABBVIE IMMUNOLOGY SCHOLARSHIP OVERVIEW
Applications will be made available on November 13, 2017 on www.AbbVieImmunologyScholarship.com.
Applications must be submitted by 12 p.m. CST on January 9, 2018.
Award recipients will be notified by April 18, 2018.
2018 Danby HSF Research Grant Funding Opportunities-Grant applications awarded. Winners to be announced soon.
July 21, 2017: The Hidradenitis Suppurativa Foundation (HSF) is seeking grant applications that encourage research into the disease hidradenitis suppurativa (HS). The goal is to stimulate the development of new research programs in the field of HS capable of competing for long-term funding from the National Institutes of Health or other agencies in the future.
If you would like to submit your proposal, please follow the instructions here: 2018-danby-hsf-research-grant-program.
Anticipated number of awards: 1-2 new grants may be awarded in 2018. Awards are contingent upon the availability of funds and the receipt of sufficiently meritorious applications.
Budget: Applicants may request up to $10,000 (direct costs only) per year.
Last year, Dr. Amanda Nelson won this prestigious grant for the following project.
The cause of hidradenitis suppurativa (HS) is unknown. HS affects 1-4% of the population (3.2-12.8 million people in the USA) and is a chronic, debilitating inflammatory skin appendage disorder, primarily occurring in the axillae (armpits) and groin with no known treatment or cure. Our laboratory is focused on understanding the cause and progression of HS. As very little is understood about this disease, we will use state-of-the-art 3D imaging technology to examine the skin architecture and skin appendages in HS skin to determine if there is a structural deficit within the skin of HS patients. In addition, we will investigate the presence of aberrant skin stem cell populations in HS lesions that may contribute to the chronic nature of this disease.
May 30, 2017: Both the states of Georgia and Michigan have proclaimed June 5-11, 2017 as Hidradenitis Suppurativa Awareness Week.
HS Foundation Participation at IDEOM (International Dermatology Outcome Measures)
New York, New York – October 15th, 2016
The HS Foundation National Coordinator of Advocacy and Support, HSF Physician Board Members, along with Hope for HS, represented the interests of patients and physicians at the IDEOM conference for HS. Physicians specializing in HS treatment, along with six HS patients, HS Advocates and Industry were present to develop consensus on the domains to be used in outcome measures for HS.
Why was the IDEOM event important? Actually, it is more than important, it is a milestone for HS. Outcome measures are used in clinical trials. Clinical trials do not always mean trials of a drug, as this can relate to quality of life, surgery or procedures, drugs (topical, oral, injectables, infusions, etc), and even diet or alternative medicine. This group decides by means of a consensus on the standardized outcomes or endpoints that are looked at to determine results for a trial.
Establishing standardized tools for HS trials is a tremendous milestone. This shows that HS is being recognized as a disease that needs more research and needs agreed upon tools, with input from both physicians and patients, to get the most valuable data from a trial.
Now that the domains have been established, the tools within the domains can be developed. The HS Foundation and Hope for HS will continue involvement in the process of developing outcome measures for HS.
We would like to thank IDEOM for their diligent work in advancing knowledge of HS.
HS Working Group at IDEOM, New York, New York – October 15th, 2016